SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of a press release issued by ICN Pharmaceuticals,
Inc. on May 22, 2002.
[Letterhead of ICN Pharmaceuticals, Inc.]
Investors: Media:
---------- ------
Joe Schepers Mariann Ohanesian Alan Charles
212-754-4422 714-545-0100, ext. 3230 714-545-0100, ext. 3013
ICN PHARMACEUTICALS ANNOUNCES ANALYST MEETING
TO DISCUSS PRO FORMA RESULTS AND 2002 GUIDANCE
COSTA MESA, CA, May 22, 2002 - ICN Pharmaceuticals (NYSE: ICN) today
announced that it will host a meeting with analysts and investors to
discuss pro forma financial results for its major business units. The
company will also discuss its growth strategy for the specialty
pharmaceutical business and guidance for 2002. The meeting will be held at
the Waldorf Astoria Hotel in New York City on Friday, May 24, 2002 at 11:00
a.m. EDT.
Analysts and investors, as well as other interested parties who cannot
attend the meeting in person are invited to participate via conference call
and Web cast. The dial-in number to participate live on this call is (719)
457-2684 and the confirmation code is 500581. A replay of the call will be
available approximately two hours following the conclusion of the
conference call through Tuesday, May 28, 2002, and can be accessed by
dialing (719) 457-0820.
The company's presentation materials will be available on ICN's Web
site prior to the start of the meeting. To access the Web cast and company
materials, go to ICN's corporate Web site at www.icnpharm.com.
ICN is an innovative, research-based global pharmaceutical company
that manufactures, markets and distributes a broad range of prescription
and non-prescription pharmaceuticals, and devices under the ICN brand name.
Its research and new product development focuses on innovative treatments
for dermatology, oncology and hepatology.
Additional information is also available on the Company's Web site at
http://www.icnpharm.com.
-------
THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. This press release contains forward-looking statements that
involve risks and uncertainties, including but not limited to, projections
of future sales, operating income, returns on invested assets, regulatory
approval processes, and other risks detailed from time to time in the
Company's Securities and Exchange Commission filings. It also assumes that
the Company's operations are not adversely affected by any disruption that
may be caused by the pending proxy contest.
###